The Scientist

» industry and developmental biology

Most Recent

image: The Prescient Placenta

The Prescient Placenta

By | August 1, 2015

The maternal-fetal interface plays important roles in the health of both mother and baby, even after birth.

1 Comment

image: HHS Partners on Ebola Drug

HHS Partners on Ebola Drug

By | July 22, 2015

The US Department of Health and Human Services will put nearly $20 million toward the development of an Ebola drug as Tekmira steps out of the space.

0 Comments

image: More Transparency in IRB-Industry Ties

More Transparency in IRB-Industry Ties

By | July 13, 2015

Conflicts of interest among institutional review board members are disclosed more often than they were a decade ago, according to a survey of academics.

0 Comments

image: CAR-T Therapies Get $1 Billion Boost

CAR-T Therapies Get $1 Billion Boost

By | July 1, 2015

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.

0 Comments

image: Organ-on-a-Chip Gets Big Pharma Boost

Organ-on-a-Chip Gets Big Pharma Boost

By | June 18, 2015

Johnson & Johnson agrees to use Emulate’s blood-clot device in three of its preclinical drug programs.

0 Comments

image: Sperm From Ovaries

Sperm From Ovaries

By | June 11, 2015

With the deletion of a single gene, female Japanese rice fish can produce sperm. 

1 Comment

image: Dino Snouts from Chicken Beaks

Dino Snouts from Chicken Beaks

By | May 13, 2015

Researchers tweak gene expression in chicken embryos that may have been crucial to the evolutionary transition from dinosaur noses to bird bills.

0 Comments

image: Follow the Funding

Follow the Funding

By | May 1, 2015

In times of budget belt-tightening at the federal level, life-science researchers can keep their work supported through private sources.  

9 Comments

image: Think Before You Fire

Think Before You Fire

By | May 1, 2015

Industry layoffs may save a few dollars, at the cost of losing the collective brainpower of thousands of scientists.

4 Comments

image: Drugmaker Teva Bids $40 Billion for Mylan

Drugmaker Teva Bids $40 Billion for Mylan

By | April 23, 2015

The Israel-based pharmaceutical company makes an unsolicited offer for a smaller, Netherlands-based rival as its main product faces competition from generics.

0 Comments

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS